EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Ribosome specialization in cancer: a spotlight on ribosomal proteins

Sofia Ramalho iD, Anna Dopler iD, William James Faller iD

NAR Cancer · 09.07.2024 · 6 (3)

DOI: 10.1093/narcan/zcae029 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift NAR Cancer, online erschienen am 09.07.2024. Verfasst von Sofia Ramalho und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, Netherlands. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nederlandse Organisatie voor Wetenschappelijk Onderzoek.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the past few decades, our view of ribosomes has changed substantially. Rather than passive machines without significant variability, it is now acknowledged that they are heterogeneous, and have direct regulatory capacity. This ‘ribosome heterogeneity’ comes in many flavors, including in both the RNA and protein components of ribosomes, so there are many paths through which ribosome specialization could arise. It is easy to imagine that specialized ribosomes could have wide physiological roles, through the translation of specific mRNA populations, and there is now evidence for this in several contexts. Translation is highly dysregulated in cancer, needed to support oncogenic phenotypes and to overcome cellular stress. However, the role of ribosome specialization in this is not clear. In this review we focus on specialized ribosomes in cancer. Specifically, we assess the impact that post-translational modifications and differential ribosome incorporation of ribosomal proteins (RPs) have in this disease. We focus on studies that have shown a ribosome-mediated change in translation of specific mRNA populations, and hypothesize how such a process could be driving other phenotypes. We review the impact of RP-mediated heterogeneity in both intrinsic and extrinsic oncogenic processes, and consider how this knowledge could be leveraged to benefit patients.

Autor:innen und Institutionen

  • Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, Netherlands.

ORCID-Profile: Sofia Ramalho, Anna Dopler, William James Faller

Förderung

  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek

Zitieren

APA

Ramalho, S., Dopler, A., & Faller, W. J. (2024). Ribosome specialization in cancer: a spotlight on ribosomal proteins. NAR Cancer, 6(3). https://doi.org/10.1093/narcan/zcae029

Vancouver

Ramalho S, Dopler A, Faller WJ. Ribosome specialization in cancer: a spotlight on ribosomal proteins. NAR Cancer. 2024;6(3). doi:10.1093/narcan/zcae029

BibTeX
@article{Ramalho2024,
  author = {Ramalho, Sofia and Dopler, Anna and Faller, William James},
  title = {Ribosome specialization in cancer: a spotlight on ribosomal proteins},
  journal = {NAR Cancer},
  year = {2024},
  volume = {6},
  number = {3},
  doi = {10.1093/narcan/zcae029}
}
Kostenlos starten →